Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
TRV130
Description:
TRV130, also called oliceridine, is a synthetic opioid drug that acts as a biased agonist of the μ-opioid receptor.
Primary topic:
Receptor Mechanisms and Signaling (32%)
Related topics:
Receptor Mechanisms and Signaling (32%),
Pain Management and Opioid Use (24%),
Anesthesia and Pain Management (9%),
Neuropeptides and Animal Physiology (8%)
Wikidata ID:
wiki/Q17142898
OpenAlex ID:
keywords/trv130
A G Protein-Biased Ligand at the μ-Opioid Receptor Is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with Morphine
2013
·
Scott M. DeWire
, Dennis S. Yamashita
, et al.
·
Journal of Pharmacology and Experimental Therapeutics
·
736
Molecular recognition of morphine and fentanyl by the human μ-opioid receptor
2022
·
Youwen Zhuang
, Yue Wang
, et al.
·
Cell
·
316
Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers
2014
·
David G. Soergel
, Ruth Ann Subach
, et al.
·
Pain
·
304
Structure–Activity Relationships and Discovery of a G Protein Biased μ Opioid Receptor Ligand, [(3-Methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the Treatment of Acute Severe Pain
2013
·
Xiao-Tao Chen
, Philip Pitis
, et al.
·
Journal of Medicinal Chemistry
·
245
A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain
2015
·
Eugene R. Viscusi
, Lynn Webster
, et al.
·
Pain
·
237
APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy
2019
·
Eugene R Viscusi
, Franck Skobieranda
, et al.
·
Journal of Pain Research
·
192
PDF
Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents
2017
·
Ahmad A Altarifi
, Bethany David
, et al.
·
Journal of Psychopharmacology
·
182
A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (µ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty
2017
·
Neil Singla
, Harold Minkowitz
, et al.
·
Journal of Pain Research
·
181
PDF
First Clinical Experience With TRV130: Pharmacokinetics and Pharmacodynamics in Healthy Volunteers
2013
·
David G. Soergel
, Ruth Ann Subach
, et al.
·
The Journal of Clinical Pharmacology
·
143
ATHENA: A Phase 3, Open-Label Study Of The Safety And Effectiveness Of Oliceridine (TRV130), A G-Protein Selective Agonist At The μ-Opioid Receptor, In Patients With Moderate To Severe Acute Pain Requiring Parenteral Opioid Therapy
2019
·
Sergio D Bergese
, Marek Brzezinski
, et al.
·
Journal of Pain Research
·
92
PDF
Biased agonism of clinically approved μ-opioid receptor agonists and TRV130 is not controlled by binding and signaling kinetics
2019
·
Mie Fabricius Pedersen
, Tomasz Marcin Wróbel
, et al.
·
Neuropharmacology
·
90
PDF
G protein‐biased kratom‐alkaloids and synthetic carfentanil‐amide opioids as potential treatments for alcohol use disorder
2019
·
Anna M. Gutridge
, Meridith T. Robins
, et al.
·
British Journal of Pharmacology
·
81
PDF
The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats
2018
·
C. Austin Zamarripa
, Shelley R. Edwards
, et al.
·
Drug and Alcohol Dependence
·
80
Mechanism of β-arrestin recruitment by the μ-opioid G protein-coupled receptor
2020
·
Amirhossein Mafi
, Soo-Kyung Kim
, et al.
·
Proceedings of the National Academy of Sciences
·
75
PDF
Abuse Potential of Biased Mu Opioid Receptor Agonists
2018
·
S. Stevens Negus
, Kevin B. Freeman
·
Trends in Pharmacological Sciences
·
62
Oliceridine for the Management of Moderate to Severe Acute Postoperative Pain: A Narrative Review
2023
·
Neil Daksla
, Ashley Wang
, et al.
·
Drug Design Development and Therapy
·
61
PDF
Assessment of structure-activity relationships and biased agonism at the Mu opioid receptor of novel synthetic opioids using a novel, stable bio-assay platform
2020
·
Lakshmi Vasudevan
, Marthe Vandeputte
, et al.
·
Biochemical Pharmacology
·
60
PDF
Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats
2019
·
Kathryn L. Schwienteck
, Kaycee E. Faunce
, et al.
·
Neuropharmacology
·
60
Approval of oliceridine (TRV130) for intravenous use in moderate to severe pain in adults
2020
·
David Lambert
, Girolamo Calo
·
British Journal of Anaesthesia
·
52
PDF
The G‐protein‐biased agents PZM21 and TRV130 are partial agonists of μ‐opioid receptor‐mediated signalling to ion channels
2019
·
Yevgen Yudin
, Tibor Rohacs
·
British Journal of Pharmacology
·
52
PDF
Oliceridine (TRV130), a Novel G Protein–Biased Ligand at the μ‐Opioid Receptor, Demonstrates a Predictable Relationship Between Plasma Concentrations and Pain Relief. I: Development of a Pharmacokinetic/Pharmacodynamic Model
2018
·
Michael J. Fossler
, Brian M. Sadler
, et al.
·
The Journal of Clinical Pharmacology
·
50
TRV130 partial agonism and capacity to induce anti‐nociceptive tolerance revealed through reducing available μ‐opioid receptor number
2021
·
Samuel Singleton
, Daniel T. Baptista‐Hon
, et al.
·
British Journal of Pharmacology
·
49
PDF
In a Rat Model of Opioid Maintenance, the G Protein–Biased Mu Opioid Receptor Agonist TRV130 Decreases Relapse to Oxycodone Seeking and Taking and Prevents Oxycodone-Induced Brain Hypoxia
2020
·
Jennifer M. Bossert
, Eugene A. Kiyatkin
, et al.
·
Biological Psychiatry
·
49
Mu-opioid Receptor (MOR) Biased Agonists Induce Biphasic Dose-dependent Hyperalgesia and Analgesia, and Hyperalgesic Priming in the Rat
2018
·
Dionéia Araldi
, Luiz F. Ferrari
, et al.
·
Neuroscience
·
42
PDF
The Utilization of Mu-Opioid Receptor Biased Agonists: Oliceridine, an Opioid Analgesic with Reduced Adverse Effects
2019
·
Ivan Urits
, Omar Viswanath
, et al.
·
Current Pain and Headache Reports
·
36
Show more works
View as search
Works count:
99
Citation count:
3,971
Year
Topic
Type